Workflow
高盛：巨子生物-2025 年上半年前瞻_ 尽管近期不确定性冲击销售，韧性利润率驱动净利润增长 20%；买入评级
GIANT BIOGENEGIANT BIOGENE(HK:02367) Goldman Sachs·2025-07-16 00:55

Mia Gu +852-2978-6973 | mia.gu@gs.com Goldman Sachs (Asia) L.L.C. | Key Data __________________________________ | | --- | 14 July 2025 | 9:28PM HKT Giant Biogene Holding (2367.HK) 1H25 Preview: Resilient margin to drive 20% NI growth despite sales hit from recent uncertainty; Buy | 2367.HK | | --- | | 12m Price Target: HK$71.00 | | Price: HK$56.75 | | Upside: 25.1% | Giant Biogene is set to release its 1H25 results around late Aug. We expect its sales/net profit to grow at 23%/20% yoy to RMB3,116m/RMB1,183m ...